All In Biotech

Drug Trial Radar · NCT04208555

Comparison of Boric Acid vs. Terconazole in Treatment of RVVC

A Randomized Comparison of Boric Acid Versus Terconazole in Treatment of Recurrent Vulvovaginal Candidiasis

Last checked: Nov 19, 2026Latest source record: Dec 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

76

Planned (sponsor's estimate)

Start

Jan 15, 2020

Primary completion

Feb 28, 2021

Study completion May 31, 2021

Sponsor

Lead sponsor
Hatem AbuHashimAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Vulvovaginal candidiasis (VVC) caused by Candida species, predominantly C. Albicans is considered one of the most common infections of the lower female genital tract affecting 75% of women at least once in their lifetime. Recurrent VVC (RVVC) is arbitrarily defined as four or more episodes every year. RVVC is a debilitating, long-term condition that can severely affect the quality of life of women. Several factors have been associated with RVVC such as prolonged use of antibiotics, inadequately treated infection, uncontrolled diabetes, immune mechanisms (e.g. HIV), oral contraceptive use as well as the resistance of non-albicans Candida species (e.g. C glabrata, C krusei) to conventional antifungal agents as azoles. Fluconazole administered orally is the most commonly used antifungal drug in the case of RVVC. However, in the last decade, fluconazole-resistant C Albicans has been reported in women with RVVC. Terconazole is a broad-spectrum, triazole antifungal treatment agent for both C Albicans and non-albicans. Its use (80 mg vaginal suppository daily for 6 days) was as effective as two doses of oral fluconazole (150 mg) in the treatment of patients with severe VVC and RVVC. Boric acid or boracic \[B(OH)3\] is a weak acid with proven antifungal action. In RVVC especially in azole-resistant strains and in non-Candida Albicans, 600 mg of the boric acid vaginal suppository is recommended once daily for 2 weeks. This regimen has a mycologic cure rate varied from 40% to 100%. However, there are no published studies comparing the intravaginal use of boric acid with terconazole for RVVC. Accordingly, a prospective randomized study in patients with RVVC will be conducted to address this important issue.

Conditions

  • Vulvovaginal Candidiasis

Interventions

  • Boric Acid Vaginal SuppositoryDrug

    Boric acid vaginal suppository (600 mg/day) for 14 days

  • Terconazole Vaginal SuppositoryDrug

    Terconazole 80 mg vaginal suppository daily for 6 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mycological cure rateTime frame: At day 15 of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.